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INTRODUCTION: The aim of the treatment of coronary artery disease (CAD) and chronic heart 
failure (CHF) is modification of cardio-vascular risk factors (blood pressure, dyslipidemia, obesity, 
glucose level). Therefore, choosing the medication for the treatment of patients with CHF and 
diabetes mellitus type 2 (DM) attention should be given for its metabolic effects. 
AIM: The goal was to determine the metabolic effects of telmisartan. 
MATERIALS AND METHODS: 98 patients of senile age with combined course of CHF due to CAD 
complicated by diabetes mellitus type 2 were under investigation. Two main groups were formed: 
A – 32 patients who were treated according to standard protocol (beta- blockers, aspirin, statin), B 
– patients for whom telmisartan in a daily dose of 40 mg was prescribed in addition to standard 
protocol. Levels of basal and post-prandial glycaemia, total cholesterol (TC), low-density 
lipoproteins (LDL), high-density lipoproteins (HDL) and triglycerides (TG) were measured before 
treatment and after 3 months. 
RESULTS: As the result of the complex treatment significant reduction of basal glycaemia for 33% 
and post-prandial glycaemia for 18% in group A (p<0,001) was observed, but normal values were 
not reached. Instead, in the group B significantly lower fasting blood glucose levels  (4,6±0,18  
mmol/L  against  8,5±0,82 mmol/L,  p<0,001)  and  levels  of  post-prandial glycaemia were detected 
together with reaching the normal values. More significant changes of blood lipids spectrum were 
observed in the group B: evident TC decrease for 16% (p<0,001), LDL – for 52% (p<0,001), TG – for 
12,5% (p<0,001) together with increase of HDL  for 48% (p<0,001) compared to the correspondent 
values before treatment. Above-mentioned hypoglycaemic,  anti-atherogenous  effects  of  
telmisartan  are  probably stipulated  by PPARγ- receptor stimulating properties. 
CONCLUSION: The addition of telmisartan to the standard protocol treatment of CHF with 
concomitant type 2 diabetes mellitus showed beneficial metabolic effects, compared with the group 
that did not receive telmisartan. 
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